联系客服

300181 深市 佐力药业


首页 公告 佐力药业:2021年度财务决算报告

佐力药业:2021年度财务决算报告

公告日期:2022-04-20

佐力药业:2021年度财务决算报告 PDF查看PDF原文

              浙江佐力药业股份有限公司

                2021 年度财务决算报告

        浙江佐力药业股份有限公司(以下简称“公司”)经中汇会计师事务所(特
    殊普通合伙)(以下简称“中汇会计师事务所”)审计,对公司 2021 年度财务报
    告出具了标准无保留意见的审计报告。中汇会计师事务所经审计认为,公司财务
    报表已经按企业会计准则的规定编制,在所有重大方面公允反映了公司 2021 年
    12 月 31 日的财务状况以及 2021 年度的经营成果和现金流量。现将公司 2021 年
    度财务决算的相关内容报告如下:

        一、2021 年度主要会计数据和财务指标

                                2021 年        2020 年    本年比上年      2019 年
                                                          增减

营业收入(元)              1,457,396,066.42  1,090,878,169.19  33.60%  911,163,975.83

归属于上市公司股东的净利润

(元)                      179,408,091.21  88,801,777.68    102.03%  25,592,842.38

归属于上市公司股东的扣除非

经常性损益的净利润(元)    173,082,925.27  83,868,492.07    106.37%  16,693,115.81

经营活动产生的现金流量净额

(元)                      251,798,511.89  279,691,036.27    -9.97%  128,942,614.45

基本每股收益(元/股)            0.2948        0.1459      102.06%      0.0421

稀释每股收益(元/股)            0.2948        0.1459      102.06%      0.0421

加权平均净资产收益率            10.83%        6.59%        4.24%        1.94%

                            2021 年末      2020 年末      本年末比上  2019 年末

                                                          年末增减

资产总额(元)              2,748,532,182.07  2,469,876,379.74  11.28%  2,050,645,692.02

归属于上市公司股东的净资产

(元)                      1,844,064,465.20  1,602,812,556.70  15.05%  1,310,354,170.19

        二、报告期内主要财务数据大幅变动的情况及原因

        (一)资产构成重大变动情况

                                                                            单位:元

                      2021 年末            2021 年初        比重

                      金额    占总资      金额      占总资  增减    重大变动说明
                              产比例                产比例

货币资金          232,302,842.53  8.45%  253,745,846.42 10.27% -1.82%

应收账款          299,924,697.18 10.91%  271,859,915.36 11.01% -0.10%


                                                                    公司主要是以“以销
                                                                    定产, 产销动态平
                                                                    衡”的方式运营,根
                                                                    据下年度的销售计划
存货              273,588,868.56  9.95%  201,441,315.80  8.16%  1.79% 和月度生产计划,并
                                                                    考虑可能发生疫情存
                                                                    在不确定性,安排生
                                                                    产任务,适量加大了
                                                                    库存。

长期股权投资        1,804,564.31  0.07%    1,656,015.93  0.07%  0.00%

固定资产          738,437,314.72 26.87%  749,195,651.75 30.33% -3.46%

                                                                    主要是本报告期公司
                                                                    增加了“综合医药制
在建工程          40,292,799.28  1.47%    896,581.92  0.04%  1.43% 剂数字化车间建设项
                                                                    目”、“103 生产线
                                                                    智能包装线项目”的
                                                                    投资所致。

使用权资产        27,594,412.97  1.00%  30,876,239.01  1.25% -0.25%

                                                                    主要根据公司年度资
短期借款          178,195,897.23  6.48%  302,849,294.47 12.26% -5.78% 金情况归还了部分到
                                                                    期的银行贷款

合同负债            3,057,627.67  0.11%    1,563,727.59  0.06%  0.05%

                                                                    主要根据公司年度资
长期借款                                30,047,895.87  1.22% -1.22% 金情况归还了全部长
                                                                    期借款

租赁负债          24,268,109.61  0.88%  28,043,313.86  1.11% -0.23%

        (二)费用情况

                                                                            单位:元

                    2021 年      2020 年    同比增减          重大变动说明

销售费用        708,498,062.63 517,609,852.80  36.88%  随销售收入增加而增加的市场投入

管理费用        85,756,153.95 83,560,821.54  2.63%

财务费用        9,195,239.24  15,401,110.20  -40.29%  贷款规模减少而减少的利息支出

                                                      为丰富产品结构及对已上市产品提
研发费用        45,633,291.42 30,386,918.42  50.17%  供学术证据和安全性数据,加大了研
                                                      发投入

        (三)现金流量表中涉及变动情况

                                                                            单位:元

            项目                  2021 年            2020 年          同比增减

经营活动现金流入小计              1,583,566,896.69    1,255,008,587.53        26.18%

经营活动现金流出小计              1,331,768,384.80      975,317,551.26        36.55%

经营活动产生的现金流量净额        251,798,511.89      279,691,036.27        -9.97%

投资活动现金流入小计              285,331,363.29      15,130,513.85        1,785.80%

投资活动现金流出小计              322,225,331.97      136,383,904.14        136.26%

投资活动产生的现金流量净额        -36,893,968.68      -121,253,390.29        69.57%

筹资活动现金流入小计              238,147,600.00      309,826,185.90        -23.14%

筹资活动现金流出小计
[点击查看PDF原文]